首页> 外文期刊>Journal of Medicinal Chemistry >Design, Synthesis, and Biological Evaluation of 1,2,3,7-Tetrahydro-6H-purin-6-one and 3,7-Dihydro-1H-purine-2,6-dione Derivatives as Corticotropin-Releasing Factor(1) Receptor Antagonists.
【24h】

Design, Synthesis, and Biological Evaluation of 1,2,3,7-Tetrahydro-6H-purin-6-one and 3,7-Dihydro-1H-purine-2,6-dione Derivatives as Corticotropin-Releasing Factor(1) Receptor Antagonists.

机译:1,2,3,7-四氢-6H-嘌呤-6-一和3,7-二氢-1H-嘌呤-2,6-二酮衍生物作为促肾上腺皮质激素释放因子的设计,合成及生物学评价(1)受体拮抗剂。

获取原文
获取原文并翻译 | 示例
           

摘要

A growing body of evidence suggests that CRF(1) receptor antagonism offers considerable therapeutic potential in the treatment of diseases resulting from elevated levels of CRF, such as anxiety and depression. A series of novel 1,2,3,7-tetrahydro-6H-purin-6-one and 3,7-dihydro-1H-purine-2,6-dione derivatives was synthesized and evaluated as corticotropin releasing factor-1 (CRF(1)) receptor antagonists. Compounds within this series, represented by compound 12d (IC(50) = 5.4 nM), were found to be highly potent CRF(1) receptor antagonists. In addition, compounds 12d and 12j were determined to be selective CRF(1) antagonists. The synthesis, structure-activity relationships and pharmacokinetic properties of compounds within this series is presented.
机译:越来越多的证据表明,CRF(1)受体拮抗作用在治疗由CRF水平升高引起的疾病(如焦虑症和抑郁症)中具有巨大的治疗潜力。合成了一系列新颖的1,2,3,7-四氢-6H-嘌呤-6-一和3,7-二氢-1H-嘌呤-2,6-二酮衍生物,并将其评价为促肾上腺皮质激素释放因子-1(CRF (1)受体拮抗剂。发现该系列中的化合物以化合物12d(IC(50)= 5.4 nM)表示是高效CRF(1)受体拮抗剂。此外,化合物12d和12j被确定为选择性CRF(1)拮抗剂。介绍了该系列化合物的合成,构效关系和药代动力学特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号